You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

Details for New Drug Application (NDA): 022560


✉ Email this page to a colleague

« Back to Dashboard


NDA 022560 describes ATELVIA, which is a drug marketed by Apil and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ATELVIA profile page.

The generic ingredient in ATELVIA is risedronate sodium. There are nineteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the risedronate sodium profile page.
Summary for 022560
Tradename:ATELVIA
Applicant:Apil
Ingredient:risedronate sodium
Patents:3
Pharmacology for NDA: 022560
Medical Subject Heading (MeSH) Categories for 022560
Suppliers and Packaging for NDA: 022560
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560 NDA Allergan, Inc. 0430-0979 0430-0979-03 4 TABLET, DELAYED RELEASE in 1 DOSE PACK (0430-0979-03)
ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560 NDA AUTHORIZED GENERIC Greenstone LLC 59762-0407 59762-0407-4 1 BLISTER PACK in 1 CARTON (59762-0407-4) / 4 TABLET, DELAYED RELEASE in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength35MG
Approval Date:Oct 8, 2010TE:ABRLD:Yes
Patent:⤷  Sign UpPatent Expiration:Jan 9, 2028Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
Patent:⤷  Sign UpPatent Expiration:Jan 9, 2028Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
Patent:⤷  Sign UpPatent Expiration:Jan 16, 2026Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022560

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560-001 Oct 8, 2010 ⤷  Sign Up ⤷  Sign Up
Apil ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560-001 Oct 8, 2010 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.